Skip to Content

Join the 'Hairy Cell Leukemia' group to help and get support from people like you.

Hairy Cell Leukemia News

Related terms: Cancer, Hairy Cell Leukemia, Leukemia, Hairy Cell, Leukemic reticuloendotheliosis, HCL

Novel Treatment, Lumoxiti Injection, Approved for 'Hairy Cell' Leukemia

Posted 13 Sep 2018 by Drugs.com

THURSDAY, Sept. 13, 2018 – Lumoxiti injection has been approved to treat certain instances of relapsed or refractory "hairy cell" leukemia (HCL), the U.S. Food and Drug Administration said Thursday. Lumoxiti (moxetumomab pasudotox-tdfk) is among a novel class of drugs called CD22-directed cytotoxins to treat HCL, the agency said. It was approved for adults who have had at least two prior ...

FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia

Posted 13 Sep 2018 by Drugs.com

September 13, 2018 – The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first ...

Childhood Cancer Death Rates Continue to Fall: CDC

Posted 16 Sep 2016 by Drugs.com

FRIDAY, Sept. 16, 2016 – The number of U.S. children who die from cancer has fallen 20 percent since 1999, and leukemia is no longer the top killer, a new federal government report shows. The decline continues a trend that began back in the 1970s, experts said. What's new is that leukemia – the most common type of childhood cancer – is no longer the leading cause of cancer deaths. Survival ...

New Immune Therapy Achieves Complete Remission in Blood Cancer Patients

Posted 16 Feb 2016 by Drugs.com

A new therapy that uses a person's immune system to attack tumors led to complete remission in terminally ill blood cancer patients, according to researchers. In a clinical trial, symptoms vanished in 94 percent of leukemia patients who received the treatment. The response rate was more than 80 percent in patients with other blood cancers, and half achieved total remission, CNBC reported. The ...

Antibody May Lower Rejection Rates After Stem Cell Transplant in Leukemia Patients

Posted 7 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 6, 2016 – People with acute leukemia who were given antibody therapy before a stem cell transplant fared better than those who didn't receive the treatment, a small study found. Stem cell transplantation allows doctors to give higher doses of cancer-killing chemotherapy, according to the American Cancer Society. However, the odds of the body rejecting the transplanted stem cells ...

End-of-Life Talk Often Comes Too Late for Blood Cancer Patients

Posted 21 Dec 2015 by Drugs.com

MONDAY, Dec. 21, 2015 – Many doctors wait too long to have end-of-life discussions with blood cancer patients, a new study finds. Researchers analyzed surveys completed by 349 blood cancer specialists, and found that 56 percent said end-of-life discussions with patients happen too late. Nearly 43 percent said they had their first end-of-life discussions with patients at less-than-ideal times, ...

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is ...

Ask a Question

Further Information

Related Condition Support Groups

Leukemia

Related Drug Support Groups

cladribine, interferon alfa-2b, moxetumomab pasudotox, Leustatin, Lumoxiti, interferon alfa-2a, pentostatin, Roferon-A, Nipent, Intron A, Cladribine Novaplus